
Cytely turns conventional microscopes into an AI‑enabled platform that autonomously captures high‑fidelity quantitative microscopy data, accelerating assay development and biological discovery. The…

Cytely turns conventional microscopes into an AI‑enabled platform that autonomously captures high‑fidelity quantitative microscopy data, accelerating assay development and biological discovery. The…
What they do: AI-enabled software that converts conventional microscopes into autonomous, quantitative microscopy platforms (B2B SaaS)
HQ / legal: Lund, Sweden (operating as Cytely AB)
Founding year: 2022
Stage / funding: Early-stage; raised a €3M round (Oct 2025) and earlier pre-seed participation
Employees: 19
Microscopy automation, single-cell imaging, assay standardization for biotech and pharmaceutical R&D
2022
Biotechnology
€3,000,000
Announced round to support international expansion of the AI-driven microscopy platform
USD 4,022,734
Crunchbase lists an earlier pre-seed round and reports Icebreaker.vc as an investor
“Investors include Ugly Duckling Ventures, Icebreaker.vc, and participation from SmiLe Venture Hub”
| Company |
|---|
What We're Building
Cytely turns any fluorescence microscope into a real-time data engine. Think of it as bringing the quantitative rigor of flow cytometry to the spatial richness of microscopy—automated segmentation, per-cell gating, phagocytosis metrics, kinetic tracking—all while maintaining the "why" through interactive image browsing.
The product is technical. The science matters. The sales motion is consultative, pilot-driven, and requires genuine fluency in microscopy workflows. You can't fake it with these customers.
What You'll Actually Do
What Success Looks Like (6–12 months)
Who Thrives HereYou should join if
You should NOT join if
What You BringMust‑haves
Nice‑to‑haves
Why This Matters
Scientists are still spending months on image analysis that should take minutes. Breakthroughs are delayed because researchers can't process the data their microscopes generate. Drug targets go unexplored. Assays stay manual and irreproducible.
Cytely's vision is to close the loop from acquisition to decision on an experiment-day timescale, not a grant cycle. We want to build a global discovery system that eventually predicts outcomes and autonomously drives research.
You're not selling software. You're accelerating biomedical research that could prevent curable disease.
Practical Details
Interview Process
One Last Thing
If you're reading this and thinking 'this sounds chaotic, risky, and like a ton of work' — you're right. It is.
But if you're also thinking 'this sounds like the opportunity to build something from zero, work on a mission that matters, and prove you can create commercial leverage at a deep-tech startup before anyone else believes it's possible' — then we should talk.
We're looking for one person. The right one.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week